How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?

More about Open Access at the Crick


Despite the availability of multiple targeted therapies, the 5-year survival rate of patients with metastatic clear cell renal cell carcinoma (ccRCC) rarely exceeds 10%. Recent insights into the mutational landscape and evolutionary dynamics of ccRCC have offered up a plausible explanation for these outcomes. The purpose of this review is to link the research findings to potential changes in clinical practice.

Journal details

Volume 25
Issue number 5
Pages 358-366
Available online
Publication date